Obesity pharmacotherapies and cognition
Science · 05.11.2026 · 394 (6824) · 633-640
DOI: 10.1126/science.aek9987 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Science, erschienen am 05.11.2026. Verfasst von Stina Börchers und 3 weiteren Autor:innen. Beteiligte Einrichtung: Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Cognition, Diabetes Mellitus, Type 2, Obesity. Die Arbeit nennt 58 Literaturangaben. Gefördert von: Sundhed og Sygdom, Det Frie Forskningsråd, HORIZON EUROPE European Research Council, Swiss National Science Foundation.
Abstract (Originalsprache)
Pharmacotherapies for obesity and type 2 diabetes are increasingly being evaluated for their effects on cognition and brain health. Evidence from preclinical models, observational cohorts, and clinical trials has intensified interest, but findings remain mixed. A central challenge is to determine whether potential cognitive effects arise from direct actions on neural circuits, indirect consequences of improved cardiometabolic health, or both. This Review examines the evidence across cardiometabolic disease, aging, and Alzheimer’s disease, focusing on glucagon-like peptide-1 (GLP-1)–based therapies and combination approaches that engage glucose-dependent insulinotropic polypeptide, glucagon, and amylin pathways. We assess how receptor pharmacology, brain exposure, metabolic context, and disease stage shape cognitive outcomes and discuss how mechanistic clarity could guide therapies aimed at preserving or improving cognition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
- Department of Physiology, Institute for Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
- Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
- Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
ORCID-Profile: Stina Börchers, Giulia Mazzini, Henrik Zetterberg, Christoffer Clemmensen
Förderung
- Sundhed og Sygdom, Det Frie Forskningsråd
- HORIZON EUROPE European Research Council
- Swiss National Science Foundation
- Swedish Research Council Formas
- Novo Nordisk Fonden
- The swedish Research Council
Zitieren
APA
Börchers, S., Mazzini, G., Zetterberg, H., & Clemmensen, C. (2026). Obesity pharmacotherapies and cognition. Science, 394(6824), 633-640. https://doi.org/10.1126/science.aek9987
Vancouver
Börchers S, Mazzini G, Zetterberg H, Clemmensen C. Obesity pharmacotherapies and cognition. Science. 2026;394(6824):633-640. doi:10.1126/science.aek9987
BibTeX
@article{Brchers2026,
author = {Börchers, Stina and Mazzini, Giulia and Zetterberg, Henrik and Clemmensen, Christoffer},
title = {Obesity pharmacotherapies and cognition},
journal = {Science},
year = {2026},
volume = {394},
number = {6824},
pages = {633--640},
doi = {10.1126/science.aek9987}
}
EUVIMED